Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Vifor Pharma Group

Extension of the postponement of the settlement of Vifor Pharma tender offer
From Vifor Pharma Group
Via Business Wire
Update on the timeline for Vifor Pharma tender offer
From Vifor Pharma Group
Via Business Wire
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients
From Vifor Pharma Group
Via Business Wire
94th Vifor Pharma Group Annual General Meeting
From Vifor Pharma Group
Via Business Wire
DIAMOND trial: Veltassa® enables patients to achieve long-term potassium control and optimized RAASi therapy
From Vifor Pharma Group
Via Business Wire
Publication of provisional end result for Vifor Pharma tender offer: Participation rate of 94 percent
From Vifor Pharma Group
Via Business Wire
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients
From Vifor Pharma Group
Via Business Wire
Vifor Pharma appoints two new members to the Executive Committee
From Vifor Pharma Group
Via Business Wire
Vifor Pharma and American Regent announce settlement of Injectafer® patent litigation
From Vifor Pharma Group
Via Business Wire
Vifor Pharma drives transformation with divestment of non-core finished drug manufacturing to CordenPharma
From Vifor Pharma Group
Via Business Wire
CSL Limited announces tender offer to acquire Vifor Pharma Ltd
From Vifor Pharma Group
Via Business Wire
Vifor Pharma comments on media speculation
From Vifor Pharma Group
Via Business Wire
Vifor Pharma comments on market speculations
From Vifor Pharma Group
Via Business Wire
VFMCRP receives positive CHMP opinion for Tavneos® for the treatment of ANCA-associated vasculitis
From Vifor Pharma Group
Via Business Wire
VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan
From Vifor Pharma Group
Via Business Wire
Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand
From Vifor Pharma Group
Via Business Wire
Tickers TVTX
Vifor Pharma’s Ferinject® granted new recommendations in updated 2021 ESC heart failure guidelines
From Vifor Pharma Group
Via Business Wire
Vifor Pharma and Cara Therapeutics announce U.S. FDA approval of KORSUVA™ injection for the treatment of moderate-to-severe pruritus in hemodialysis patients
From Vifor Pharma Group
Via Business Wire
Tickers CARA
VFMCRP announces positive results of phase-III clinical trial of Velphoro® in China
From Vifor Pharma Group
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.